Advances in cervical cancer control and future perspectives

Area of Science:

• Oncology
• Virology
• Gynecology

Background:

• Persistent high-risk human papillomavirus (HR-HPV) infection is the primary cause of cervical cancer.
• HPV DNA detection and prophylactic vaccines targeting HPV 16 and 18 are key preventive strategies.
• Cervical cancer screening remains crucial for both vaccinated and unvaccinated women, adapting to new technologies.

Purpose of the Study:

• To explore advanced diagnostic and management strategies for cervical disease beyond conventional screening.
• To evaluate the utility of novel biomarkers for improving the management of HPV-positive women.
• To discuss future perspectives in predicting cervical cancer progression.

Main Methods:

• Review of current and emerging technologies for HPV detection and cervical cancer management.
• Analysis of HPV DNA detection, viral load, E6/E7 transcript detection, and p16INK4a over-expression.
• Consideration of future approaches like gene methylation status determination.

Main Results:

• HPV DNA testing offers higher sensitivity than cytology but lower specificity due to transient infections.
• Detection of viral oncogene E6/E7 transcripts is a promising tool for follow-up of HPV DNA-positive individuals.
• p16INK4a over-expression aids in confirming cervical neoplasia but has limited reproducibility in borderline cases.

Conclusions:

• While HPV vaccination is important, cervical cancer screening and advanced molecular diagnostics are essential for comprehensive management.
• Emerging biomarkers like E6/E7 transcripts and potentially gene methylation status hold promise for refining patient management and predicting disease progression.
• Further standardization and validation of new technologies are needed for optimal clinical application in cervical disease management.